freeze-thaw cycle raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-14. Anything still debated is marked as such rather than presented as settled.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
This is a list of Roman legions, including key facts about each legion, primarily focusing on the Principate (early Empire, 27 BC – 284 AD) legions, for which there exists substantial literary, epigraphic and archaeological evidence.
== Immunity == Immune cells can be divided into myeloid cells and lymphoid cells. Myeloid cells, including macrophages and neutrophils, are especially implicated in the respiratory burst. They are phagocytic, and the respiratory burst is vital for the subsequent degradation of internalised bacteria or other pathogens. This is an important aspect of the innate immunity. Respiratory burst requires a 10 to 20 fold increase in oxygen consumption through NADPH oxidase (NOX2 in humans) activity. NADPH is the key substrate of NOX2, and bears reducing power. Glycogen breakdown is vital to produce NADPH. This occurs via the pentose phosphate pathway. The NOX2 enzyme is bound in the phagolysosome membrane. Post bacterial phagocytosis, it is activated, producing superoxide via its redox centre, which transfers electrons from cytosolic NADPH to O2 in the phagosome.
In humans, the only post-synaptic receptor at which amphetamine is known to bind is the 5-HT1A receptor, where it acts as an agonist with low micromolar affinity. The full profile of amphetamine's short-term drug effects in humans is mostly derived through increased cellular communication or neurotransmission of dopamine, serotonin, norepinephrine, epinephrine, histamine, CART peptides, endogenous opioids, adrenocorticotropic hormone, corticosteroids, and glutamate, which it affects through interactions with CART, 5-HT1A, EAAT3, TAAR1, VMAT1, VMAT2, and possibly other biological targets. Amphetamine also activates seven human carbonic anhydrase enzymes, several of which are expressed in the human brain. Dextroamphetamine displays higher binding affinity for DAT than levoamphetamine, whereas both enantiomers share comparable affinity at NET; Consequently, dextroamphetamine produces greater CNS stimulation than levoamphetamine, roughly three to four times more, but levoamphetamine has slightly stronger cardiovascular and peripheral effects. Dextroamphetamine is also a more potent agonist of TAAR1 than levoamphetamine.
=== Psoriasis === Pro-inflammatory (M1) macrophages are responsible for the progression of psoriasis. They are mainly derived from infiltrated monocytes. M1 macrophages' population could be as high as 60% of all the infiltrated immune cells during the disease onset. They are the primary source of TNF-a, which leads to lesion development when there is a prolonged production of TNF-a. TNF-a could also trigger M1 polarisation, which leads to further exaggeration of the disease. M1 macrophage ablation via adalimumab administration could alleviate psoriasis.
== Death == On February 21, 1961, Jones died of lung cancer at age 67 in Minneapolis, Minnesota, predeceasing his wife, Lucille. In an obituary in the Saturday Evening Post, it was said, "Most engineers start at the bottom of a project and work up, but Fred takes a flying leap to the top of the mountain and then backs down, cutting steps for himself and the rest of us as he goes." Jones continued filing for patents almost up until his death, receiving his last patent in February 1960.
Sources: en.wikipedia.org
=== 2019 recall of Ranitidine products === In 2019, Dr. Reddy's recalled all ranitidine products in the US market due to contamination with the carcinogen N-nitrosodimethylamine (NDMA). Months later, all brands of ranitidine were recalled and it was taken off the US market, as the carcinogen was an unavoidable byproduct.
=== Agonists === α-MSH and ACTH are both peptides derived from processed POMC, and both activate the other MCR's, but ACTH is the only agonist ligand for MC2R (ACTH receptor). This suggests that there is more protein-related specificity for binding MC2R.
=== Co-franchising === By the mid-to late-1990s, Church's Chicken and hamburger chain White Castle announced their co-franchise, in which both companies would sell their own separate products, while operating in some shared restaurant spaces, with some shared personnel. In Canada, Church's Chicken items were once available in Harvey's restaurants, but the co-venture was discontinued.
== Literature == Hofmann K, Lucas RA, SAX SM (1952). "The chemical nature of the fatty acids of Lactobacillus arabinosus". J Biol Chem. 195 (2): 473–85. doi:10.1016/S0021-9258(18)55754-9. PMID 14946156.{{cite journal}}: CS1 maint: multiple names: authors list (link) Dennis W. Grogan, John. E. Cronan, Jr. (1997), "Cyclopropane ring formation in membrane lipids of bacteria", Microbiology and Molecular Biology Reviews, vol. 61, no. 4, pp. 429–441, Bibcode:1997MMBR...61..429G, doi:10.1128/mmbr.61.4.429-441.1997, PMC 232619, PMID 9409147{{citation}}: CS1 maint: multiple names: authors list (link)
Gusts of up to 82 mph are reported, with yellow weather warnings in place for Scotland, and much of Northern Ireland and northern England. 22 December Strong winds continue to cause disruption in parts of the UK, with Heathrow Airport cancelling around 100 flights. A BBC News investigation discovers that a Church of England priest at the centre of a sexual abuse case was twice reappointed to a senior role during Archbishop of York Stephen Cottrell's time as Bishop of Chelmsford. In response, Cottrell says he regrets the handling of the incident. 23 December Revised Office for National Statistics data shows economic growth was at 0% between July and September. A number of Morrisons stores have been beset with technical problems regarding discounts and deliveries. Chocolate manufacturer Cadbury is stripped of its Royal Warrant of Appointment after being included on the list of Appointments since 1854. 24 December Two NHS hospitals in London are reported to be trialling artificial intelligence (AI) in order to detect signs of type 2 diabetes in patients. The UK government announces that the UK motor industry is being consulted on how the phasing out of petrol and diesel engines by 2030 would work. The Met Office forecasts mild and dry weather for Christmas Day throughout much of the UK. 25 December Off Dunkirk on the north coast of France, French authorities rescue 30 people from a small boat, whilst allowing those wishing to cross the Channel to England, to continue into British waters to be taken into the custody of British authorities.
Sources: en.wikipedia.org
=== Glutamate transport === Citicoline lowers increased glutamate concentrations and raises decreased ATP concentrations induced by ischemia. Citicoline also increases glutamate uptake by increasing expression of EAAT2, a glutamate transporter, in vitro in rat astrocytes. It is suggested that the neuroprotective effects of citicoline after a stroke are due in part to citicoline's ability to decrease levels of glutamate in the brain. This is in part due to an indirect decrease in the extrasynaptic NMDA-TRMP4 death signaling pathway. It's important to also note it is only the extrasynaptic NMDA receptors responsible for excitotoxicity.
In July 2018, the Food and Drug Administration approved enzalutamide, developed by Pfizer and Astellas Pharma for patients with castration-resistant prostate cancer. In August 2018, Pfizer signed an agreement with BioNTech to conduct joint research and development activities regarding mRNA-based influenza vaccines. In October 2018, effective January 1, 2019, Albert Bourla was promoted to CEO, succeeding Ian Read, his mentor. In July 2019, the company acquired Therachon for up to $810 million, expanding its rare disease portfolio through Therachon's recombinant human fibroblast growth factor receptor 3 compound, aimed at treating conditions such as achondroplasia. Also in July, Pfizer acquired Array Biopharma for $10.6 billion, boosting its oncology pipeline. In August 2019, Pfizer merged its consumer health business with that of GlaxoSmithKline, into a joint venture owned 68% by GlaxoSmithKline and 32% by Pfizer, with plans to make it a public company. The transaction built on a 2018 transaction where GlaxoSmithKline acquired Novartis' stake in the GSK-Novartis consumer healthcare joint business. The transaction followed negotiations with other companies including Reckitt Benckiser, Sanofi, Johnson & Johnson, and Procter & Gamble. In September 2019, Pfizer initiated a study with the CDC Foundation to investigate the tracking of healthcare-associated infections, scheduled to run through to June 2023. In December 2019, Pfizer awarded the CDC Foundation a further $1,948,482 to continue its cryptococcal disease screening and treatment research in nine African countries.
Non-pathogenic organisms can become pathogenic given specific conditions, and even the most virulent organism requires certain circumstances to cause a compromising infection. Some colonizing bacteria, such as Corynebacteria sp. and Viridans streptococci, prevent the adhesion and colonization of pathogenic bacteria and thus have a symbiotic relationship with the host, preventing infection and speeding wound healing.
=== Electrical seasoning === Electrical seasoning involves running an electric current through the lumber causing heat to be generated and drying the wood. This method is expensive but is fast and uniform quality.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.